Lynparza (olaparib) vs Truqap (capivasertib)
Lynparza (olaparib) vs Truqap (capivasertib)
Lynparza (olaparib) is a PARP inhibitor used primarily to treat certain types of cancers, including ovarian, breast, pancreatic, and prostate cancers, particularly in individuals with specific genetic mutations such as BRCA. It works by exploiting the DNA repair weaknesses in cancer cells, causing them to die. On the other hand, Truqap (capivasertib) is an AKT inhibitor being investigated for its potential in treating various cancers, including breast cancer, by targeting a different pathway involved in cell growth and survival; however, as of my knowledge cutoff in 2023, capivasertib has not yet been approved for clinical use. When deciding between these medications, it is crucial to consider the specific type of cancer, genetic mutations present, and the approval status of the drugs, consulting with a healthcare provider for personalized medical advice.
Difference between Lynparza and Truqap
| Metric | Lynparza (olaparib) | Truqap (capivasertib) |
|---|---|---|
| Generic name | olaparib | capivasertib |
| Indications | BRCA-mutated ovarian cancer, breast cancer, pancreatic cancer, prostate cancer | Currently being investigated for treatment of advanced solid tumors |
| Mechanism of action | Poly (ADP-ribose) polymerase (PARP) inhibitor | AKT protein kinase inhibitor |
| Brand names | Lynparza | Truqap (investigational, not yet a brand name) |
| Administrative route | Oral | Oral (assumed as it is in clinical trials) |
| Side effects | Anemia, nausea, fatigue, vomiting, respiratory infections, blood count abnormalities | Not fully characterized, but may include diarrhea, hyperglycemia, rash, and fatigue |
| Contraindications | Hypersensitivity to olaparib or any of the excipients | Not fully established, likely similar to other kinase inhibitors |
| Drug class | Poly (ADP-ribose) polymerase (PARP) inhibitor | AKT protein kinase inhibitor |
| Manufacturer | AstraZeneca and Merck & Co. (MSD outside the US and Canada) | AstraZeneca |
Efficacy
Lynparza (Olaparib) Efficacy in Breast Cancer
Lynparza, the brand name for olaparib, is a targeted therapy known as a PARP inhibitor. It has shown efficacy in treating breast cancer, particularly in patients with a germline BRCA mutation. In clinical trials, olaparib has been effective in delaying disease progression in patients with HER2-negative metastatic breast cancer who also have a BRCA mutation. The FDA has approved Lynparza for use in patients who have previously been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting. Patients with hormone receptor-positive (HR+) breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine treatment.
Studies such as the OlympiAD trial have demonstrated that olaparib significantly improves progression-free survival compared to standard chemotherapy. In this study, patients with HER2-negative metastatic breast cancer and a germline BRCA mutation experienced a median progression-free survival of 7.0 months with olaparib compared to 4.2 months with chemotherapy. This highlights the potential of Lynparza to offer a more effective treatment option for this specific patient population.
Truqap (Capivasertib) Efficacy in Breast Cancer
Truqap, known by its generic name capivasertib, is an investigational drug that targets the AKT signaling pathway, which is often altered in cancer cells. While not yet approved by regulatory agencies, capivasertib has been studied in clinical trials for its efficacy in treating breast cancer. It has been evaluated in combination with other cancer therapies, such as fulvestrant, in patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.
Early clinical trials have shown that capivasertib, when used in combination with fulvestrant, can improve progression-free survival in patients with advanced breast cancer who have an AKT pathway alteration. For instance, the FAKTION trial demonstrated that the combination of capivasertib and fulvestrant significantly extended progression-free survival compared to fulvestrant and placebo. These results suggest that Truqap could become a valuable treatment option for patients with breast cancer characterized by alterations in the AKT pathway, pending further clinical development and regulatory approval.
Regulatory Agency Approvals
Lynparza
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Health Canada
-
Therapeutic Goods Administration (TGA), Australia
-
Medsafe (NZ)
Truqap
-
Food and Drug Administration (FDA), USA
Access Lynparza or Truqap today
If Lynparza or Truqap are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us